Clinical Trials Logo

Myxoid/Round Cell Liposarcoma clinical trials

View clinical trials related to Myxoid/Round Cell Liposarcoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06083883 Suspended - Synovial Sarcoma Clinical Trials

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Start date: March 27, 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.

NCT ID: NCT05120271 Recruiting - Clinical trials for Hepatocellular Carcinoma

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

DUET-1
Start date: May 18, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.

NCT ID: NCT03399448 Terminated - Multiple Myeloma Clinical Trials

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Start date: September 5, 2018
Phase: Phase 1
Study type: Interventional

This is a first-in-human trial proposed to test HLA-A*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.

NCT ID: NCT03132922 Active, not recruiting - Ovarian Cancer Clinical Trials

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Start date: May 15, 2017
Phase: Phase 1
Study type: Interventional

This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. This study has a substudy component that will investigate the safety and tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10 subjects.

NCT ID: NCT02609984 Terminated - Sarcoma Clinical Trials

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

Start date: April 29, 2015
Phase: Phase 2
Study type: Interventional

This is an open-label Phase 2 randomized study that will examine the use of the study agents, CMB305 (sequentially administered LV305 which is a dendritic cell-targeting viral vector expressing the New York Esophageal Squamous Cell Carcinoma 1 gene [NY-ESO-1] and G305 which is a NY-ESO-1 recombinant protein plus glucopyranosyl lipid adjuvant-stable emulsion [GLA-SE]) in combination with atezolizumab or atezolizumab alone, in participants with locally advanced, relapsed or metastatic sarcoma (synovial or myxoid/round cell liposarcoma) expressing the NY-ESO-1 protein. There is no formal primary hypothesis for this study.

NCT ID: NCT02059850 Withdrawn - Clinical trials for Recurrent Adult Soft Tissue Sarcoma

NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Start date: July 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best way to give NY-ESO-1 specific T cells after cyclophosphamide in treating patients with advanced synovial sarcoma or myxoid/round cell liposarcoma. Placing a gene that has been created in the laboratory into white blood cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving NY-ESO-1 specific T cells with cyclophosphamide may kill more tumor cells.